New drug tested for Ultra-Rare, dangerous cholesterol disorder
NCT ID NCT05217667
Summary
This study is testing an experimental drug called ARO-ANG3 for people with a rare, severe genetic condition that causes extremely high cholesterol from birth. The main goal is to see if the drug is safe and can effectively lower 'bad' cholesterol (LDL-C) over 24 weeks. Participants receive two doses and are monitored for 36 weeks, with an option to continue treatment for up to two more years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Québec, Quebec, G1V 4W2, Canada
-
Research Site 2
Chicoutimi, Quebec, G7H 7K9, Canada
-
Research Site 3
Nedlands, Western Australia, 6009, Australia
-
Research Site 4
Mount Sinai, New York, 10029, United States
-
Research Site 5
Cincinnati, Ohio, 45227, United States
-
Research Site 7
Johannesburg, 2193, South Africa
-
Research Site 8
Camperdown, New South Wales, 2050, Australia
Conditions
Explore the condition pages connected to this study.